Get Ahead of the Competition

Looking to take your ex-U.S. strategy to the next level? With a state-of-the-art clinical facility in Canada, Altasciences has the capacity and decades of expertise to submit your CTA six to nine weeks earlier than an IND.

We can help get you into the clinic faster—schedule a chat today!

Must-watch videos:

	Co-located Canadian Ophthalmology Center for All Your Early Phase Development Needs
	Accelerate Your Data With Our Canadian Co-located Clinic and Lab
	Montréal Clinic Mini Tour

We are pleased to announce a substantial expansion of our laboratory facilities in Columbia, Missouri. 

The newly added 8,000-square-foot space is designed to emulate our existing bioanalytical laboratory in Laval, Canada. It will feature cutting-edge equipment to support nonclinical and clinical studies carried out in the United States. 

Our laboratory is conveniently located near our Kansas City clinic and shares a location with our preclinical site in Columbia, providing seamless solutions for nonclinical and clinical sample analysis. 

Contact us for all your bioanalytical needs. 

You may also be interested in the following webpages: 

• Bioanalytical Services 
• Bioanalytical Platforms 
• Flow Cytometry Capabilities

More Models, More Options

The miniature swine has emerged as a viable non-rodent alternative for nonclinical studies. Our team has extensive experience with miniature swine in several therapeutic areas, including dermal, cardiovascular, metabolic diseases, inflammation, and wound healing.

Want to explore this promising option further?

DISCOVER MORE
 

You may also be interested in the following:

Webinars:
- Miniature Swine Model Selection Criteria for Toxicology and Pharmacology Studies
- Downsized Miniature Swine: A New Spin on the Oldest Model
Interview: Selecting Miniature Swine Models for Your Toxicology Study​​​​​​
 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.

Every day, we are committed to creating life-changing drugs. As partners in drug development, we understand that our work has a profound impact on people across the world. Our dedication drives us forward, and we are honored to be part of such an important and impactful field.

Altasciences' Amber Malloy understands that the drugs she works on have the power to change people's lives.

In this video, Amber shares her journey and what motivates her to bring her best every day.

Watch the video

Altasciences Ophthalmic Clinical Offering: A Unique Integration of Expertise, Location, and Passion

At Altasciences, we understand the unique challenges of developing treatments for retinal disease. That's why we've created an integrated approach that brings together clinical and scientific expertise specific to ophthalmology. From our state-of-the-art equipment, streamlined processes, to a co-located ophthalmic clinic, every element of our offering is designed to help move treatments forward and improve patient outcomes. 

Watch as Dr. William Foster, Retinal Specialist and Principal Investigator, explains why Altasciences is the ideal partner for your ophthalmic clinical trials.

Speak with our experts to discuss your ophthalmic drug development needs.

Have five minutes? Take a look at these resources: 

Webpages:

• End-To-End Ophthalmic Drug Development Services
• Clinical Research Services

Scientific Journal: Navigating the Complexities of Ophthalmic Drug Development
 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

Leading Partner in CNS Drug Development and Manufacturing

In honor of Mental Health Awareness month, we asked our CDMO Vice President and Scientific Advisor, Dennis DiBiagio, what specific expertise is required to manufacture drugs that treat central nervous system (CNS) disorders, including mental disabilities.

Watch our latest clip of Ask an Altascientist.

                                         

Speak with Dennis today about the unique and most advantageous reason drug sponsors choose to partner with us for their CNS drug development!
 
SEND DENNIS A MESSAGE
 

You may also be interested in these related resources:

•    Webpage: Global CDMO for Manufacturing and Analytical Services
•    Interview: Manufacturing of Highly Potent APIs and Controlled Substances
•    Podcast: Key Considerations as You Move From Discovery to Preclinical to Clinical

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
 

In this issue of The Altascientist, we detail the complexities of central nervous system (CNS) drug development programs. In addition, we share how partnering with an integrated CRO/CDMO can reduce your timelines by up to 40% as your compound advances through each study phase. 

Topics covered include: 

• Preclinical safety and toxicity testing 
• Formulation and manufacturing for nonclinical and clinical studies 
• Maximizing early phase clinical trials 
• Bioanalytical considerations 

DOWNLOAD NOW 

Questions? Consult with our experts and tell us how we can support your program.

Related resources that may interest you: 

• Podcast: High Potency Manufacturing Solutions 
• Webinar: Practical Approaches When Conducting Clinical Trials With Psychedelics 
• Educational Video: Development Strategies for Neurological Drugs 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.